|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In L-NAME treated rats, relative to Ad.Null or saline administration, Ad.CMV-hAM-4F2 (i) reduced augmented cardiomyocyte membrane protein oxidation and mRNA expression of pro-oxidant (p22phox) and anti-oxidant (SOD-3, GPx) genes; (ii) attenuated increased cardiomyocyte width and mRNA expression of hypertrophic (sk-alpha-actin) and cardio-endocrine (ANP) genes; (iii) did not attenuate hypertension.
|
20798523 |
2010 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
CTD_human |
The effect of p22(phox) -930A/G, A640G and C242T polymorphisms of NADPH oxidase on peripheral and central pressures in healthy, normotensive individuals.
|
20505675 |
2010 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Exercise training, NADPH oxidase p22phox gene polymorphisms, and hypertension.
|
19516159 |
2009 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The -930A/G polymorphism of the CYBA gene (that codes p22phox, a major component of the NADPH oxidase) has been associated with human hypertension and with a reduction in NADPH oxidase activity.
|
19043982 |
2008 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
LHGDN |
Regulation of NADPH oxidase subunit p22(phox) by NF-kB in human aortic smooth muscle cells.
|
18158642 |
2008 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The -930G allele of p22-phox has been associated with higher promoter activity, increased NAD(P)H oxidase-mediated oxidative stress and hypertension.
|
17314996 |
2007 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
LHGDN |
Potential candidate genes in these regions that have been implicated in diabetic nephropathy and/or renal damage in models of hypertension include CYBA (or P22PHOX) (16q24), NOX1 (10q22), and NOX3 (6q25.1-q26).
|
17336700 |
2007 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
CTD_human |
Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney.
|
17324946 |
2007 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Potential candidate genes in these regions that have been implicated in diabetic nephropathy and/or renal damage in models of hypertension include CYBA (or P22PHOX) (16q24), NOX1 (10q22), and NOX3 (6q25.1-q26).
|
17336700 |
2007 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
LHGDN |
A novel CYBA variant, the -675A/T polymorphism, is associated with essential hypertension.
|
17620958 |
2007 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The C242T polymorphism was not in linkage disequilibrium with the -930A/G CYBA promoter variation, which also associates with hypertension.
|
16794479 |
2006 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
RGD |
Serum thiobarbituric acid reactive substances concentration and aortic superoxide anion concentration were estimated to assess oxidative stress.8-Br-cAMP (5 mg/kg, i.p.) or atorvastatin (30 mg/kg, p.o.) prevented hypertension-induced attenuation of acetylcholine-induced endothelium-dependent relaxation, impairment of vascular endothelial lining, decrease in expression of mRNA for endothelial nitric oxide synthase (eNOS), serum nitrite/nitrate concentration and increase in expression of mRNA for p22phox, superoxide anion and serum TBARS.
|
17109653 |
2006 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
LHGDN |
NADPH oxidase-mediated oxidative stress: genetic studies of the p22(phox) gene in hypertension.
|
16115038 |
2006 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
CTD_human |
Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade.
|
16685210 |
2006 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Logistic analysis indicated that the CYBA/G(-930)A polymorphism was associated with hypertension in male subjects.
|
15671602 |
2005 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Polymorphisms in the p22phox gene promoter could determine susceptibility to NAD(P)H-mediated oxidative stress in humans and animals with hypertension.
|
16026320 |
2005 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Furthermore the identification of genetic polymorphisms in the effectors involved in the pathophysiology of hypertension or in the response to anti-hypertensive drugs, such as the p22phox subunit of NADPH oxidase, alpha-adducin or adrenergic receptors, has promoted the prospective of both better understanding of hypertension and individualized strategies for its treatment.
|
14965315 |
2004 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Recently we reported an association of -930A/G polymorphism in the human p22phox gene promoter with hypertension.
|
15210651 |
2004 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension.
|
12729892 |
2003 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Increased free radical production in hypertension due to increased expression of the NADPH oxidase subunit p22(phox) in lymphoblast cell lines.
|
11910303 |
2002 |
|
Kidney Failure, Chronic
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
Our results suggested that rs1049255 polymorphism of CYBA modified the risk of ESRD (p = 0.019; OR = 0.625; 95%CI = 0.424-0.921).
|
26627442 |
2016 |
|
Kidney Failure, Chronic
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
The same association was found with ESRD (p = 0.028 and p = 0.033 for CYBA TC+TT and RAGE 374AA, respectively).
|
26607824 |
2016 |
|
Kidney Failure, Chronic
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, a functional variant in the promoter of the CYBA gene was associated with lower eGFR and with prevalence and incidence of diabetic nephropathy and ESRD in type 1 diabetic patients.
|
25862415 |
2015 |
|
Kidney Failure, Chronic
|
0.550 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that assessment of the C242T CYBA polymorphism of the NADPH oxidase may be useful in identifying the risk for developing cardiovascular disease in ESRD patients.
|
21045268 |
2010 |
|
Kidney Failure, Chronic
|
0.550 |
Biomarker
|
disease |
CTD_human |
Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure.
|
19420110 |
2009 |